ClariPi Inc.
ClariPulmo is an AI-powered tri-functional solution for lung CT images. Our deep learning model provides quantitative analysis of low-attenuation and high-attenuation lesions. In combination with ClariCTAI it reduces noise induced bias with 3D reporting.
Information source: Vendor
Last updated: Oct. 4, 2023

General Information

Product name ClariPulmo
Company ClariPi Inc.
Subspeciality Chest
Modality CT
Disease targeted COPD, emphysema, pneumonia, interstitial lung disease, COVID-19.
Key-features Automatic segmentation and visualization of lungs and airways, LAA/HAA quantification, emphysema reporting
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), report suggestion

Technical Specifications

Data characteristics
Population No restrictions
Input CT, contrast or non-contrast
Input format DICOM
Output Volume rendering, automated report (two LAA and two HAA reports), heatmap overlay
Output format DICOM SR
Integration Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration CIS (Clinical Information System), Integration via AI marketplace or distribution platform, Stand-alone third party application
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 10 - 60 seconds


Certified, Class IIa , MDD
FDA 510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE) ClariPulmo is a non-invasive image analysis software for use with CT images which is intended to aid the assessment of lung lesions (e.g., emphysema, pneumonia, etc). The software is designed to support the physician in confirming the presence or absence as well as quantification of physician identified lung lesions. The software will provide automated segmentation of the lungs and quantification of low-attenuation and high-attenuation areas within the segmented lungs by using predefined Hounsfield unit thresholds. The software displays by color the segmented lungs and identified lesions. ClariPulmo provides optional denoising and kernel normalization functions for an improved detection and quantification of lung lesions in cases when CT images were taken at low-dose conditions or with sharp reconstruction kernels.


Market presence
On market since 03-2022
Distribution channels Blackford, Eureka Clinical AI, deepcOS,
Countries present (clinical, non-research use) 3
Paying clinical customers (institutes) 5
Research/test users (institutes) 3
Pricing model Pay-per-use, Subscription, One-time license fee
Based on Number of installations, Number of analyses


Peer reviewed papers on performance

  • Emphysema quantification using low-dose computed tomography with deep learning–based kernel conversion comparison (read)

Non-peer reviewed papers on performance
Other relevant papers